Panacea Biotec share jumps on 10,335 dengue trial enrolment

Market focus shifts to Panacea’s late-stage dengue vaccine work

Panacea Biotec drew investor attention after it disclosed a key milestone in its dengue vaccine programme. The company said it has completed enrolment for the Phase III clinical trial of its dengue vaccine candidate, DengiAll. The update came through an exchange filing dated January 7, referenced under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. In the following session, the stock moved sharply higher in intraday trade. The development matters because Phase III enrolment completion is a major operational step in vaccine development, particularly for a disease area where large, multi-site studies are required. It also adds clarity to the programme’s execution timeline after several years of development work.

Share price reaction: stock rose as the filing hit the tape

Panacea Bio’s share price surged as much as 6% to ₹407.60 during Thursday’s trading session following the company’s disclosure on trial enrolment. Separately, a market data snapshot in the provided material showed Panacea Biotec at ₹403.00 with a +2.03% move, reflecting another reference point around mid-January 2026. The broader takeaway from both data points is that the stock was actively reacting to company-specific developments and trading remained volatile around news flow. The report also described the stock as volatile amid weak market sentiment, indicating that price moves were not limited to a single session. Investors typically monitor such healthcare names closely when clinical trial milestones are released, because progress updates can influence expectations around timelines and costs.

What Panacea Biotec announced to exchanges

In the exchange filing dated January 7, the company said enrolment of study participants for the DengiAll Phase III clinical trial has been completed. Panacea Biotec disclosed that it enrolled 10,335 study participants. The filing also described the follow-up structure: each subject will be followed for two years after receiving either the vaccine or a placebo. The stated purpose of the follow-up is to evaluate the candidate’s efficacy and immune response. The company framed the update as a milestone under SEBI LODR disclosure norms, signalling that it views the programme as material to investors.

Trial design details: two-year follow-up after vaccine or placebo

The Phase III study design described in the provided text includes long-duration follow-up to track outcomes over time. A two-year follow-up is relevant in vaccines because it can help assess both protection and durability of immune response. Panacea Biotec’s disclosure also confirms that the study uses a placebo arm, which is a common clinical approach for late-stage efficacy assessment when feasible and permitted by ethics and regulations. The company did not provide interim efficacy results in the provided material, only operational progress on enrolment. That distinction is important because enrolment completion does not imply an outcome on efficacy, but it does suggest the study has advanced to the next phase of monitoring and data capture.

About DengiAll: a tetravalent, single-dose dengue vaccine candidate

Panacea Biotec described DengiAll as a tetravalent dengue vaccine candidate under development in India. It is formulated as a single-dose shot. The vaccine contains live, attenuated strains of all four dengue virus serotypes in one dose: DEN1, DEN2, DEN3 and DEN4. The company stated that DengiAll is expected to become India’s first indigenous single-dose dengue vaccine. It also flagged a potential launch aimed for 2027. While the statement sets a directional timeline, the provided content does not include specific regulatory filing dates or submission plans beyond the ongoing trial.

How the programme reached Phase III: DCGI approval and a long R&D timeline

The provided text linked the Phase III start to a regulatory step in 2024. In an August 14, 2024 filing, the company said it commenced the Phase III clinical trial in India after receiving approval from the Drugs Controller General of India (DCGI). The DengiAll programme was launched at Panacea Biotec in 2006, following licensing and transfer of novel attenuated tetravalent dengue virus strains between Panacea Biotec and the US National Institutes of Health. Panacea Biotec also noted it has been developing the vaccine since 2008, highlighting the time-intensive nature of dengue vaccine development. These disclosures place the current Phase III milestone in the context of a multi-year research and clinical pathway.

Prior trial work and partnerships: Phase I/II follow-up and ICMR MoU

Before the current Phase III effort, Panacea Biotec conducted Phase I/II clinical trials in the Indian population. The company said a three-year safety follow-up from that earlier work was completed in 2020. It further disclosed that, in March 2022, Panacea Biotec and the Indian Council of Medical Research (ICMR) signed an MoU to carry out Phase III clinical trials in India. The Phase III study was planned across 19 trial sites nationwide, involving 10,335 participants, which matches the completed enrolment figure shared in the January filing. Together, these points show that the Phase III programme is structured as a large, multi-site study with institutional collaboration.

Financial snapshot: Q1 profit turnaround and exceptional items

The provided material also included a quarterly financial update that adds context to investor interest. Panacea Biotec reported a consolidated net profit of ₹41 crore in Q1, compared with a loss of ₹158 crore in the year-ago period. Revenue increased 44% to ₹1,667 crore. The company recorded an exceptional item of ₹113 crore, including ₹85.80 crore from a settlement with Apotex Inc. and ₹27.40 crore from brand sales. While the filing on DengiAll focuses on clinical progress, these numbers help explain why the stock can react strongly to company updates in general, since both pipeline and financial factors are in focus.

Stock performance and valuation metrics cited in the material

The report said Panacea Bio’s share price gained 7.27% in the past five sessions and nearly 21% in a month, while also stating the scrip declined by over 11% over a year. Separately, a returns table in the provided text showed: 1 Day -4.15%, 1 Week 0.51%, 1 Month 4.23%, 1 Year 29.28%, 3 Years 205.98%, and 5 Years 106.4%. The dataset also listed a 52-week high of ₹581.90 and a 52-week low of ₹259.70, and another line cited a 52-week high of ₹581 on May 15, 2025 and a 52-week low of ₹282.15 on February 28, 2025. Key metrics cited included PE ratio 228.06, EPS (TTM) ₹1.87, PB ratio 3.29, beta 2.85, and market capitalisation ₹2,618.16 crore in one table.

Other recent triggers mentioned: tax demands, UNICEF orders, and legal settlement

Beyond the dengue vaccine programme, the provided content referenced other developments that can influence sentiment. It noted Panacea Biotec received three tax demand orders worth 93.8 million rupees, which is ₹9.38 crore, on December 24. It also described UNICEF orders for the supply of bivalent oral polio vaccine: an additional order for 40 million doses valued at about ₹44 crore for delivery in the third quarter of calendar year 2025, and earlier orders in the same calendar year for 115 million doses valued at about ₹127 crore. Separately, the material referenced a settlement of a patent dispute with Sanofi Healthcare India, stating Sanofi agreed not to market the infringing product and withdrew its opposition to Panacea’s patent amendment.

Key facts table: trial milestone, stock move, and financial highlights

Why the enrolment milestone matters for investors

From a market perspective, completion of Phase III enrolment reduces one execution risk: recruiting a large participant base across multiple sites. It also shifts attention to follow-up, case accrual, and data timelines, all of which can affect how quickly a company can progress to the next regulatory step. The company’s mention of a potential 2027 launch sets an indicative horizon for investors tracking the programme, but the provided text does not include definitive regulatory submission dates. The stock’s high beta of 2.85, as cited, aligns with the observed sensitivity to news-driven moves. Meanwhile, the financial snapshot showing a swing to profit, rising revenue, and a sizeable exceptional item indicates that near-term performance can also be shaped by settlements and one-offs.

Conclusion: milestone reached, next phase is two-year follow-up

Panacea Biotec’s disclosure confirms that its DengiAll Phase III dengue vaccine trial has completed enrolment of 10,335 participants across 19 sites, with two years of follow-up planned for each subject. The stock reacted positively in intraday trade after the announcement, reflecting investor attention on pipeline execution. Alongside the clinical update, the company’s Q1 numbers and disclosed exceptional items provide additional context for market interest. The next clearly stated step in the programme, based on the provided information, is the ongoing follow-up to evaluate efficacy and immune response, with the company indicating a potential launch targeted for 2027.